Tag: Resistance to therapy

Search News
Categories
Archives
Understanding the role of cancer’s circular genome in tumour evolution

23rd September 2022

New research, co-led by Dr Benjamin Werner from Barts Cancer Institute at Queen Mary University of London, indicates that the circular DNA structures present in around a third of cancers lead to extensive genetic diversity within tumours, giving them the ability to adapt rapidly to environmental stress and resist targeted cancer treatment.

Read more

BCI researcher receives new Pancreatic Cancer UK Fellowship

20th July 2022

Congratulations to Dr Audrey Lumeau, Postdoctoral Researcher at Barts Cancer Institute, Queen Mary University of London, who has received a Career Foundation Fellowship from the charity Pancreatic Cancer UK to investigate chromosomal instability in pancreatic cancer and its role in therapy resistance.

Read more

In conversation with Professor Marco Gerlinger

20th May 2022

This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.

Read more

Rewiring the biology of leukaemia cells to reverse drug resistance

20th April 2022

Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukaemia cells. By rewiring the inner workings of the cancer cells, the team was able to prime leukaemia cells for sensitivity to treatment in the laboratory.

Read more

Blood test predicts chemotherapy resistance in prostate cancer

11th November 2021

Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.

Read more

Overcoming drug resistance in breast cancer

28th October 2021

In recognition of Breast Cancer Awareness Month, we spoke with Dr Ioanna Keklikoglou, Lecturer and Group Leader in the Centre for Tumour Microenvironment at Barts Cancer Institute, Queen Mary University of London. Dr Keklikoglou’s research focuses on understanding the molecular and cellular mechanisms that control resistance to anti-cancer therapies in breast cancer.

Read more

Search News
Categories
Archives